Table 1.

Patient clinicopathological characteristics

Sample ID	Age	Pre-treatment PSA (ng/ml)	Pathological stages	Gleason score	Risk group based on NCCN guidelines
B15	67	5.4	cT2a cN0 cM0	3 + 4	IR
B16	76	15.8	cT2a cN0 cM0	4 + 3	IR
B17	78	6.3	cT2b cN0 cM0	3 + 4	IR
B03	82	24.4	cT1c cN0 cM0	8	HR
B60	68	17.6	cT2a cN0 M0	3 + 4	IR
C73	66	0.9	pT2a pN0 M0	3 + 4	IR
B09	71	13.30	cT3a cN0 M0	4 + 5	HR
C05	74	0.40	pT3 pN0 M0	3 + 4	HR
C12	67	0.20	pT3a pN0 M0	3 + 4	HR
B71	54	7.2	cT1c cN0 cM0	3 + 3	IR
C59	73	0.8	pT3a pN0 cM0	4 + 4	HR

IR intermediate risk group, HR high risk group, NCCN National Comprehensive Cancer Network